BioStratum appoints Claus Kühl as President and CEO

Research Triangle Park, N.C. -- September 28, 1999 -- BioStratum Incorporated, the world leading biotechnology company in basal lamina research, today announced the appointment of Claus Kühl, M.D., Ph.D., as President
and Chief Executive Officer. Dr. Kühl was previously President of ZymoGenetics and a corporate Vice President for Novo Nordisk A/S, a leading diabetes care company.
Dr. Archie Prestayko, BioStratum's previous CEO and current Chairman, will continue with BioStratum and focus his attention on the Company's clinical development programs.

"Claus brings a solid background in diabetes and a
proven record of effective leadership to BioStratum",
said Dr. Wesley Fox, Executive Vice President. "With Pyridorin™ in clinical trials, our lead drug candidate for diabetic kidney disease, and a number of new drug candidates emerging, Claus has the right background and proven leadership to take our company to the next level."

While at Novo Nordisk, Dr. Kühl held a number of positions including President of the Pharmaceuticals Division and President of the Diabetes Care Division. He also served as Chairman of the W.H.O. affiliated Steno Diabetes Center, Copenhagen, Denmark.

"The strength of the company's science, and the quality and commitment of its scientists and management team, made joining BioStratum an easy decision," said Dr Kühl. "BioStratum's lead drug candidate Pyridorin has great potential as an effective treatment for diabetic kidney disease, a life-threatening complication of diabetes. In addition, the Company's basal lamina research has identified an anti-angiogenesis drug candidate, Angiocol™, close to entering clinical trials, and a number of new therapeutic opportunities for the future."

"Claus is a proven executive with a strong background in diabetes," said Dr. Prestayko. "We are fortunate to have Claus on board to lead BioStratum in its next phase of growth."

BioStratum Incorporated is developing proprietary therapeutics based on scientific advances in basal lamina research. The company's drug candidates are directed against novel basal lamina targets involved in degenerative and invasive disease processes fundamental to diabetes, cancer and kidney disease. BioStratum is funded by a group of US and European private investors including two leading Scandinavian venture firms specializing in the life sciences, HealthCap of Stockholm, Sweden and BankInvest of Copenhagen, Denmark.